Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.

Peng JiangYan ZhangJiadong CuiXiuxiu WangYu Li

Published in: Thoracic cancer (2021)

Icotinib combined with bevacizumab or rh-endostatin has a stronger inhibitory effect on tumor growth than single-target drug in vivo, with no additional side effects.

Keyphrases

endothelial cells
drug induced
induced pluripotent stem cells
metastatic colorectal cancer
recombinant human